2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. Interleukin Related Isoform

Interleukin Related

 

Interleukin Related Related Products (691):

Cat. No. Product Name Effect Purity
  • HY-N7038
    Phytohemagglutinin
    		Activator
    Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, Phaseolus vulgaris, is a T-cell activator. Phytohemagglutinin stimulates human mononuclear leukocytes, inducing the expression of ChAT mRNA and potentiating ACh synthesis. Phytohemagglutinin induces dose- and time-dependent toxicity in THP-1 monocytes/macrophages, alters cellular morphology, causes organelle dysfunction, and increases the expression of NF-κB, COX2, IL-1β.
  • HY-P99366A
    Tezepelumab (anti-TSLP)
    		≥99.0%
    Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma.
  • HY-154629
    Sesame Oil
    		Inhibitor ≥98.0%
    Sesame Oil is a vegetable oil. Sesame Oil can be extracted from the seeds of Sesamum indicum L. Sesame Oil decreases NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4 and nitric oxide. Sesame Oil has antitumor activity against malignant melanoma. Sesame Oil has protective effects against liver damage caused by various agents such as Cisplatin (HY-17394) and Acetaminophen (HY-66005). Sesame Oil shows antinociceptive and anti-inflammatory activities.
  • HY-17007
    Saquinavir
    		Inhibitor 99.56%
    Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
  • HY-P9950
    Omalizumab
    		Inhibitor 99.70%
    Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research. The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
  • HY-P991218
    Anti-IL11 Antibody (X203)
    		Inhibitor 98.53%
    Anti-IL11 Antibody (X203) is a human-derived IgG1, κ type antibody inhibitor, targeting to human IL-11. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P10935A
    Amilo-5MER TFA
    		Inhibitor 99.63%
    Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases.
  • HY-P991201
    REGN-7257
    		Inhibitor
    REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003).
  • HY-108810
    Canakinumab
    		Inhibitor 99.64%
    Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.
  • HY-P3211A
    Nangibotide TFA
    		Inhibitor 99.86%
    Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
  • HY-P99162
    Nemolizumab
    		Inhibitor 99.93%
    Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD).
  • HY-N0890
    Tubeimoside I
    		Inhibitor 99.96%
    Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases.
  • HY-P9956
    Siltuximab
    		≥99.0%
    Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
  • HY-P9925
    Brodalumab
    		Inhibitor 99.18%
    Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis.
  • HY-N0405
    Orientin
    		Inhibitor 99.73%
    Orientin is a neuroprotective agentinhibits which has anti-inflammation, anti-oxidative, anti-tumor, and cardio protection properties. Orientin inhibits the levels of IL-6, IL-1β and TNF-α. Orientin increases IL-10 level. Orientin exhibits neuroprotective effect by inhibits TLR4 and NF-kappa B signaling pathway. Orientin can used in study neuropathic pain.
  • HY-P99550
    Tozorakimab
    		Inhibitor 98.82%
    Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease.
  • HY-P99339
    Tebentafusp
    		99.90%
    Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.
  • HY-113556
    Sappanone A
    		Inhibitor 99.87%
    Sappanone A is an orally active homoisoflavone found in sappan L. Sappanone A is a PDE4 and NF-κB inhibitor with anti-inflammatory and antioxidant effect. Sappanone A induces HO-1 expression through activation of Nrf2 pathway. Sappanone A also inhibits RANKL-induced osteoclastogenesis. Sappanone A has great potential in the research of inflammation-related and cardiovascular .
  • HY-P99519
    Vixarelimab
    		Inhibitor
    Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.
  • HY-12220
    MM-102
    		99.39%
    MM-102 (HMTase Inhibitor IX) is a cell-permeable and tightly binding inhibitor of MLL1-WDR5 interaction (IC50=2.4 nM). MM-102 can specifically inhibit the growth and induce apoptosis of leukemia cells containing MLL1 fusion protein, and reduce renal fibrosis and inflammation in mice with ischemia-reperfusion injury. In addition, MM-102 also acts as an H3K4 histone methyltransferase inhibitor to improve the development of porcine somatic cell nuclear transfer (SCNT) embryos.